Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Related Keywords

Texas ,United States ,American ,Emily Henderson ,John Heymach ,American Association For Cancer Research ,Genentech ,Bristol Myers Squibb ,Serono ,Jazz Pharmaceuticals ,Eli Lilly Co ,Novartis ,Janssen Pharmaceuticals ,Boehringer Ingelheim ,Spectrum Pharmaceuticals ,Astrazeneca ,University Of Texas Md Anderson Cancer Center ,Cancer Center ,American Association ,Cancer Research ,Annual Meeting ,Neck Medical Oncology ,Mirati Therapeutics ,Eli Lilly ,Curio Science ,Blueprint Medicines ,Cancer ,Immunotherapy ,Lung Cancer ,Surgery ,Fell ,Chemotherapy ,Non Small Cell Lung Cancer ,Perioperative ,Pharmaceuticals ,Placebo ,Research ,Small Cell Lung Cancer ,Herapeutics ,